Developer docs
API playgroundTry for free, no card

Search company profiles

PathAI

Full company profile

uuid00008ez

Namestring
PathAI
Legal namestring
PathAI, Inc.
Websiteurl
pathai.com
Company typeenum
Private
Founded yearint
2016
Descriptiontext

PathAI is a Boston-based AI-powered digital pathology company founded in 2016 that develops software, algorithms, and lab services used by biopharma sponsors, anatomic pathology laboratories, academic medical centers, and reference labs to improve diagnostic accuracy, accelerate drug development, and operationalize digital pathology workflows. The company's commercial surface spans two customer segments: BioPharma (drug sponsors and clinical trial operators) and Anatomic Pathology (clinical laboratories and health systems), with the stated mission of improving patient outcomes through AI-enabled pathology.

The core product is AISight, a cloud-native, open-platform Image Management System (IMS) that serves as the central hub for case management, slide review, and AI deployment across pathology workflows. AISight Dx is FDA 510(k)-cleared and CE-IVD-marked for primary diagnosis in the US and EEA/UK/Switzerland, integrated with Hamamatsu, Leica Aperio, Roche VENTANA, and Philips scanners and with major LIS systems via the AISight Link open API. PathAI's AI portfolio includes dozens of proprietary algorithms—PathExplore (600+ HIFs across 14 cancer indications), LiverExplore and AIM-MASH (1,000+ HIFs and the first AI-powered pathology Drug Development Tool qualified by both FDA and EMA for MASH trials), AIM-HI UC and IBDExplore for ulcerative colitis, AIM-PD-L1 and AIM-IHC Breast Panel for biomarker quantification, AIM-TumorCellularity and ArtifactDetect/TumorDetect for workflow, and the PLUTO/PLUTO-4 multimodal pathology foundation models. The Multi-Partner AI Portfolio on AISight embeds 40+ third-party algorithms (Deep Bio, Paige, Visiopharm, DoMore, Mindpeak, Stratipath, Primaa), and the company operates a CAP/CLIA-certified GCLP central pathology lab.

PathAI generates revenue through a diversified mix of streams: SaaS subscriptions and enterprise licensing of AISight and AISight Dx to biopharma and AP labs (100+ institutions), central pathology lab services for biopharma clinical trials, real-world data products licensed from quantitative HIF datasets, companion diagnostics development and commercialization, and a new Precision Pathology Network (launched July 2025) that monetizes data and algorithm access across a federated lab network. The company has raised approximately $355M+ in venture funding across multiple rounds led by General Catalyst, General Atlantic, D1 Capital Partners, and Kaiser Permanente, with strategic investors including Labcorp, Bristol-Myers Squibb, and Merck. On May 7, 2026, Roche entered into a definitive merger agreement to acquire PathAI for up to $1.05 billion, with closing expected in the second half of 2026.

Short descriptiontext

PathAI develops AI-powered digital pathology software and central lab services for biopharma drug development and clinical diagnostics. Its AISight platform integrates proprietary algorithms—including PLUTO foundation models and disease-specific biomarker panels—for primary diagnosis, trial endpoints, and laboratory workflow across global pathology laboratories.

Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
251–500
akta.pro rankint
HeadquartersBoston, United States
HQ citystring
Boston
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
digital pathology, AI pathology algorithms, biomarker quantification, clinical trial analytics, companion diagnostics
Industry4 codes
PRIMARYHLACALAC
Vendor Neutral Archive (VNA) & Enterprise Imaging Repositories
Healthcare & Life Sciences/Digital Health & Health IT/Medical Imaging Informatics (PACS/RIS/VNA) & Radiology IT
SECONDARYHLAGAJAM
Clinical Trial Informatics (EDC/CTMS/eCOA/eTMF)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLACAOAJ
Site & Investigator Platforms (Site Payments, Feasibility, Activation)
Healthcare & Life Sciences/Digital Health & Health IT/Clinical Trials & Research Informatics (eCOA/ePRO/EDC)
SECONDARYHLACAOAB
eCOA/ePRO/eDiary & Patient-Facing Data Collection
Healthcare & Life Sciences/Digital Health & Health IT/Clinical Trials & Research Informatics (eCOA/ePRO/EDC)
NAICS code3 codes
  • Diagnostic Imaging Centers621512
  • Software Publishers5132
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • Surgical & Medical Instruments & Apparatus3841
  • Services-Prepackaged Software7372
Product category
AI-Powered Digital Pathology
Social media profiles3 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model6 records
1Central Pathology Lab Services
TypeProfessional Services
Description

PathAI operates an in-house CAP/CLIA-certified GCLP histopathology lab providing end-to-end clinical trial services for biopharma partners including receipt/processing/staining, scanning, manual central pathology reads, AI-powered reads, and reporting. Currently 12 active or upcoming trials across 8+ biopharma partners.

pathai.com
2AISight Platform SaaS Subscription
TypeSubscription Recurring
Description

SaaS-based AISight Clinical Trials platform with cloud-based secure access, GCP/GCLP compliant, ISO 27001 certified, 21 CFR Part 11 compliant. Sold to biopharma and anatomic pathology labs as recurring software subscription.

pathai.com
3AISight Dx Enterprise IMS Licensing
TypeLicensing Royalties
Description

Enterprise digital pathology platform (AISight/AISight Dx) deployed to anatomic pathology institutions across academic medical centers, reference labs, health systems, and biopharma as image management system. Revenue from enterprise licensing to 100+ institutions.

pathai.com
4Real-World Data Products
TypeData Monetisation
Description

License quantitative histopathology data products (PathExplore HIFs) linked to structured clinical and molecular data from partner reference labs and TCGA. Available free to academic researchers; licensed for non-academic partners.

pathai.com
5Companion Diagnostics Development & Commercialization
TypeProfessional Services
Description

Bespoke diagnostic assays and AI-powered companion diagnostics including SaMD design, validation, regulatory and market access strategy, commercialization via partnerships across healthcare ecosystem.

pathai.com
6Clinical Trial Services & Translational Research
TypeManaged Services
Description

AI-powered endpoint measurement, patient enrollment/stratification, prospective algorithm development under GCP/GCLP/CAP/CLIA, integration with 80% of global central lab providers. Includes AI-powered histology for trial enrollment and endpoint assessment.

globenewswire.com
Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 11 records shown
1AISight
Description

Cloud-native, open-platform enterprise image management system for digital pathology workflows; includes AISight Dx (FDA 510(k) cleared and CE-IVD marked) for primary diagnosis.

pathai.com
+10 more records
Core offering1 text field

PathAI develops and sells AI-powered digital pathology software and services. The company's flagship AISight platform (and its FDA-cleared/CE-IVD-marked AISight Dx variant) serves as a cloud-native enterprise image management system used by 100+ anatomic pathology institutions for primary diagnosis, workflow optimization, and AI-driven biomarker quantification. PathAI also operates a CAP/CLIA-certified GCLP central pathology lab delivering end-to-end clinical trial services, companion diagnostic development, and real-world histopathology data products to 8+ biopharma partners.

Differentiator
Functional benefit
Problem solved
Product and service15 records
1AISight Image Management System (IMS)
CategoryDigital Pathology Platform
Description

Cloud-native, open-platform enterprise image management system for anatomic pathology, serving as the central hub for case management, image management, and embedded AI applications. Sold to academic medical centers, reference labs, health systems, and biopharma. Research Use Only in the US.

2AISight Dx Digital Pathology Platform
CategoryDigital Pathology Platform (Regulated)
Description

Cloud-native digital pathology platform FDA 510(k) cleared (with PCCP) for primary diagnosis in the US (Hamamatsu NanoZoomer S360MD, Leica Aperio GT 450 DX, Roche VENTANA DP200/DP600) and CE-IVD marked in the EEA, UK, and Switzerland. Streamlines diagnostic workflows with intelligent case management, slide review, and collaboration.

3AISight Clinical Trials Platform
CategoryClinical Trials SaaS Platform
Description

Secure, cloud-based SaaS platform that enables AI-powered algorithms and digital pathology reads in prospective and retrospective clinical trials, supporting eligibility, stratification, response monitoring, quality control, and exploratory analysis. GCP/GCLP-compliant with 21 CFR Part 11 and ISO 27001 certification.

4Precision Pathology Network (PPN)
CategoryDigital Pathology Network / Program
Description

First global network of digital anatomic pathology laboratories powered by AISight, providing early AI algorithm access, real-world data monetization, biopharma-sponsored evidence-generation studies, and clinical development partnerships to member labs.

5Central Pathology Laboratory Operations
CategoryCentral Lab Services
Description

In-house CAP/CLIA-certified GCLP histopathology lab providing end-to-end clinical trial services for biopharma partners, including receipt/processing/staining, scanning, manual central pathology reads, AI-powered reads, and reporting. Currently 12 active or upcoming trials across 8+ biopharma partners.

6Companion Diagnostics Development & Commercialization
CategoryCompanion Diagnostics Services
Description

Bespoke diagnostic assay development, AI-powered companion diagnostics, SaMD design, validation, regulatory and market access strategy, and commercialization via healthcare ecosystem partnerships for biopharma.

7PathExplore
CategoryTumor Microenvironment Analysis
Description

AI-powered panel of histopathology features that spatially characterize the tumor microenvironment (TME) from H&E whole slide images with single-cell resolution, delivering >600 unique Human Interpretable Features (HIFs) per sample across 14 cancer indications. For Research Use Only.

8LiverExplore (AIM-MASH+)
CategoryLiver Histopathology Analysis
Description

AI-powered panel of >1,000 quantitative HIFs that spatially characterize liver tissue biopsy microarchitecture from H&E whole slide images for MASH and other liver diseases, including automated detection of >20 tissue regions, >10 cell types, and fibrosis subtyping. For Research Use Only.

9IBDExplore
CategoryInflammatory Bowel Disease Analysis
Description

AI-powered panel of histopathology features that spatially characterize the inflammatory microenvironment from H&E whole slide images, with 12 tissue regions, 10 cell types, and >1000 HIFs. Built and assessed on Ulcerative Colitis biopsies. For Research Use Only.

10IHCExplore
CategoryIHC Biomarker Quantification
Description

AI-powered IHC assay quantification at tissue, cellular, and subcellular resolution; extracts key histopathological features from IHC slide images and transforms IHC whole-slide images into quantitative insights for biomarker development. For Research Use Only.

11AIM-MASH AI Assist
CategoryMASH Drug Development Tool
Description

AI-based measurement tool providing MASLD Activity Score (MAS) component grades and fibrosis stages to aid a single central pathologist for enrollment/inclusion of patients into clinical phase 2 and 3 MASH trials and evaluation of study outcomes. First AI-powered pathology Drug Development Tool with FDA and EMA qualification.

12AIM-IHC Breast Panel
CategoryBreast Biomarker Quantification
Description

AI-based measurement panel of key breast cancer biomarkers — HER2, ER, PR, and Ki-67 — fully integrated into the AISight Image Management System. Multi-clone and multi-scanner compatible with explainable AI heatmaps using additive multiple instance learning. For Research Use Only.

13PathAssist Derm
CategoryDermatopathology AI
Description

AI-powered dermatopathology workflow solution with FDA Breakthrough Device Designation that analyzes digital pathology whole slide images of skin lesions and assists pathologists in their review. For Research Use Only.

14PLUTO / PLUTO-4 Pathology Foundation Model
CategoryPathology Foundation Model
Description

State-of-the-art pathology foundation model (with PLUTO-4 as latest frontier version) that enhances AI-powered pathology tools via transfer learning and fine-tuning for downstream tasks, combining histopathology images with language for multimodal disease classification.

15AIM-HI Ulcerative Colitis (AIM-HI UC)
CategoryUlcerative Colitis Endpoint Scoring
Description

AI-powered Geboes subgrade scoring tool assisting pathologists in accurately and reproducibly measuring histological stage for ulcerative colitis clinical trial endpoint assessment, trained on >9,000 biopsies from six clinical trials; bridges Geboes, Robarts Histopathology Index, and Nancy Histological Index scoring systems. For Research Use Only.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeOthers
Description

Labcorp is a strategic investor in PathAI since 2019 and recently expanded collaboration to deploy AISight Dx nationwide (Feb 2026). Labcorp is both a major customer of PathAI's digital pathology platform and an anatomic pathology services competitor through its diagnostics business.

TypeDirect peer
Description

Proscia offers a cloud-native digital pathology platform (Concentriq) with embedded AI applications and a biopharma services offering, directly competing with PathAI's AISight IMS and PathExplore products. Proscia serves similar anatomic pathology labs and biopharma customers in translational research and clinical trials.

TypeDirect peer
Description

Owkin is an AI pathology and biopharma services company that builds proprietary AI models on histopathology data for drug development and diagnostic applications. Owkin's biopharma-focused AI pathology approach directly overlaps PathAI's clinical trial services and companion diagnostics offerings.

4Tempus AI
TypeBroad incumbent
Description

Tempus AI is a broader precision medicine and AI-driven diagnostics company with multimodal data capabilities including pathology, genomics, and clinical data. Tempus competes in biopharma services and RWD monetization, with adjacent pathology AI capabilities that overlap PathAI's clinical trial services and data products.

TypeDirect peer
Description

Ibex is a direct competitor in AI-powered cancer diagnostics, with deployments at multiple tier-1 health systems globally for prostate, breast, and gastric cancer detection. Ibex's Galen platform competes head-to-head with PathAI's AISight Dx and AIM-* diagnostic algorithms in primary diagnosis workflows.

TypeDirect peer
Description

Visiopharm is a peer AI pathology company offering APPs for breast cancer biomarkers (ER, PR, Ki-67, HER2) and PD-L1, with IVDR clearance in EU/UK. Visiopharm is integrated as a partner algorithm within PathAI's AISight ecosystem but also competes as a standalone pathology AI platform.

TypeDirect peer
Description

Paige AI is a direct competitor in AI-powered digital pathology, offering FDA-authorized AI products for prostate, breast, and pan-cancer diagnostic pathology integrated into enterprise pathology workflows. Paige.AI's diagnostic suite directly overlaps PathAI's AIM-IHC Breast Panel and AISight Dx offerings, serving the same biopharma and anatomic pathology lab customers.

TypeBroad incumbent
Description

Roche Diagnostics is the parent/acquirer of PathAI and a broad incumbent in the diagnostics industry with the VENTANA scanner installed base and navify digital pathology platform. PathAI's AISight IMS will integrate into Roche Diagnostics' broader portfolio upon closing of the acquisition announced May 2026.

TypeEmerging player
Description

Deep Bio is a Korean AI pathology company offering CE-IVD-marked DeepDx Prostate diagnostic aid, integrated as a partner algorithm in PathAI's AISight Multi-Partner AI Portfolio. Deep Bio recently trimmed headcount and is relying on distribution partnerships including PathAI and Roche Diagnostics.

TypeEmerging player
Description

Mindpeak is an emerging AI pathology company with CE-IVD-marked AI for breast cancer biomarker analysis (HER2, ER/PR, Ki-67) and lung PD-L1. Mindpeak is integrated into PathAI's AISight Multi-Partner AI Portfolio but also operates as an independent pathology AI vendor.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
Yes

Docs URL, Description

Integration17 records

Each record includes

Title, Type, Description, Source

AI capability13 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature11 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles15 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance9 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds6 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors20 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

PathAI

AI-Powered Digital Pathologypathai.com

PathAI develops AI-powered digital pathology software and central lab services for biopharma drug development and clinical diagnostics. Its AISight platform integrates proprietary algorithms—including PLUTO foundation models and disease-specific biomarker panels—for primary diagnosis, trial endpoints, and laboratory workflow across global pathology laboratories.

What PathAI does

PathAI is a Boston-based AI-powered digital pathology company founded in 2016 that develops software, algorithms, and lab services used by biopharma sponsors, anatomic pathology laboratories, academic medical centers, and reference labs to improve diagnostic accuracy, accelerate drug development, and operationalize digital pathology workflows. The company's commercial surface spans two customer segments: BioPharma (drug sponsors and clinical trial operators) and Anatomic Pathology (clinical laboratories and health systems), with the stated mission of improving patient outcomes through AI-enabled pathology.

The core product is AISight, a cloud-native, open-platform Image Management System (IMS) that serves as the central hub for case management, slide review, and AI deployment across pathology workflows. AISight Dx is FDA 510(k)-cleared and CE-IVD-marked for primary diagnosis in the US and EEA/UK/Switzerland, integrated with Hamamatsu, Leica Aperio, Roche VENTANA, and Philips scanners and with major LIS systems via the AISight Link open API. PathAI's AI portfolio includes dozens of proprietary algorithms—PathExplore (600+ HIFs across 14 cancer indications), LiverExplore and AIM-MASH (1,000+ HIFs and the first AI-powered pathology Drug Development Tool qualified by both FDA and EMA for MASH trials), AIM-HI UC and IBDExplore for ulcerative colitis, AIM-PD-L1 and AIM-IHC Breast Panel for biomarker quantification, AIM-TumorCellularity and ArtifactDetect/TumorDetect for workflow, and the PLUTO/PLUTO-4 multimodal pathology foundation models. The Multi-Partner AI Portfolio on AISight embeds 40+ third-party algorithms (Deep Bio, Paige, Visiopharm, DoMore, Mindpeak, Stratipath, Primaa), and the company operates a CAP/CLIA-certified GCLP central pathology lab.

PathAI generates revenue through a diversified mix of streams: SaaS subscriptions and enterprise licensing of AISight and AISight Dx to biopharma and AP labs (100+ institutions), central pathology lab services for biopharma clinical trials, real-world data products licensed from quantitative HIF datasets, companion diagnostics development and commercialization, and a new Precision Pathology Network (launched July 2025) that monetizes data and algorithm access across a federated lab network. The company has raised approximately $355M+ in venture funding across multiple rounds led by General Catalyst, General Atlantic, D1 Capital Partners, and Kaiser Permanente, with strategic investors including Labcorp, Bristol-Myers Squibb, and Merck. On May 7, 2026, Roche entered into a definitive merger agreement to acquire PathAI for up to $1.05 billion, with closing expected in the second half of 2026.

PathAI firmographics

Firmographics
Name
PathAI
Legal name
PathAI, Inc.
Website
https://pathai.com
Company type
Private
Founded year
2016
Operating status
Acquired
Headcount range
251–500 employees
Short description
PathAI develops AI-powered digital pathology software and central lab services for biopharma drug development and clinical diagnostics. Its AISight platform integrates proprietary algorithms—including PLUTO foundation models and disease-specific biomarker panels—for primary diagnosis, trial endpoints, and laboratory workflow across global pathology laboratories.
Ownership category
akta.pro rank

PathAI industry classification

Industry
Product category
AI-Powered Digital Pathology
NAICS
Diagnostic Imaging Centers (621512), Software Publishers (5132), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Surgical & Medical Instruments & Apparatus (3841), Services-Prepackaged Software (7372)
akta.pro industry
PRIMARYHLACALAC
Vendor Neutral Archive (VNA) & Enterprise Imaging Repositories
Healthcare & Life Sciences/Digital Health & Health IT/Medical Imaging Informatics (PACS/RIS/VNA) & Radiology IT
SECONDARYHLAGAJAM
Clinical Trial Informatics (EDC/CTMS/eCOA/eTMF)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLACAOAJ
Site & Investigator Platforms (Site Payments, Feasibility, Activation)
Healthcare & Life Sciences/Digital Health & Health IT/Clinical Trials & Research Informatics (eCOA/ePRO/EDC)
SECONDARYHLACAOAB
eCOA/ePRO/eDiary & Patient-Facing Data Collection
Healthcare & Life Sciences/Digital Health & Health IT/Clinical Trials & Research Informatics (eCOA/ePRO/EDC)

Keywords

  • Digital pathology
  • AI pathology algorithms
  • Biomarker quantification
  • Clinical trial analytics
  • Companion diagnostics

Where PathAI is headquartered

Location

Headquarters

HQ city
Boston
HQ country
United States
HQ region
North America

Markets served

PathAI business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Central Pathology Lab Services: PathAI operates an in-house CAP/CLIA-certified GCLP histopathology lab providing end-to-end clinical trial services for biopharma partners including receipt/processing/staining, scanning, manual central pathology reads, AI-powered reads, and reporting. Currently 12 active or upcoming trials across 8+ biopharma partners.
  2. AISight Platform SaaS Subscription: SaaS-based AISight Clinical Trials platform with cloud-based secure access, GCP/GCLP compliant, ISO 27001 certified, 21 CFR Part 11 compliant. Sold to biopharma and anatomic pathology labs as recurring software subscription.
  3. AISight Dx Enterprise IMS Licensing: Enterprise digital pathology platform (AISight/AISight Dx) deployed to anatomic pathology institutions across academic medical centers, reference labs, health systems, and biopharma as image management system. Revenue from enterprise licensing to 100+ institutions.
  4. Real-World Data Products: License quantitative histopathology data products (PathExplore HIFs) linked to structured clinical and molecular data from partner reference labs and TCGA. Available free to academic researchers; licensed for non-academic partners.
  5. Companion Diagnostics Development & Commercialization: Bespoke diagnostic assays and AI-powered companion diagnostics including SaMD design, validation, regulatory and market access strategy, commercialization via partnerships across healthcare ecosystem.
  6. Clinical Trial Services & Translational Research: AI-powered endpoint measurement, patient enrollment/stratification, prospective algorithm development under GCP/GCLP/CAP/CLIA, integration with 80% of global central lab providers. Includes AI-powered histology for trial enrollment and endpoint assessment.

Go-to-market motion1 record

PathAI product offering

Product offering

Core offering

PathAI develops and sells AI-powered digital pathology software and services. The company's flagship AISight platform (and its FDA-cleared/CE-IVD-marked AISight Dx variant) serves as a cloud-native enterprise image management system used by 100+ anatomic pathology institutions for primary diagnosis, workflow optimization, and AI-driven biomarker quantification. PathAI also operates a CAP/CLIA-certified GCLP central pathology lab delivering end-to-end clinical trial services, companion diagnostic development, and real-world histopathology data products to 8+ biopharma partners.

Differentiator

Problem solved

Functional benefit

Brands

  • AISight: Cloud-native, open-platform enterprise image management system for digital pathology workflows; includes AISight Dx (FDA 510(k) cleared and CE-IVD marked) for primary diagnosis.
  • PathExplore
  • IHCExplore
  • LiverExplore
  • IBDExplore
  • AIM-MASH
  • AIM-IHC Breast Panel
  • PathAssist Derm
  • AIM-HI UC
  • PLUTO
  • Precision Pathology Network

Products and services

  • AISight Image Management System (IMS) Cloud-native, open-platform enterprise image management system for anatomic pathology, serving as the central hub for case management, image management, and embedded AI applications. Sold to academic medical centers, reference labs, health systems, and biopharma. Research Use Only in the US.
  • AISight Dx Digital Pathology Platform Cloud-native digital pathology platform FDA 510(k) cleared (with PCCP) for primary diagnosis in the US (Hamamatsu NanoZoomer S360MD, Leica Aperio GT 450 DX, Roche VENTANA DP200/DP600) and CE-IVD marked in the EEA, UK, and Switzerland. Streamlines diagnostic workflows with intelligent case management, slide review, and collaboration.
  • AISight Clinical Trials Platform Secure, cloud-based SaaS platform that enables AI-powered algorithms and digital pathology reads in prospective and retrospective clinical trials, supporting eligibility, stratification, response monitoring, quality control, and exploratory analysis. GCP/GCLP-compliant with 21 CFR Part 11 and ISO 27001 certification.
  • Precision Pathology Network (PPN) First global network of digital anatomic pathology laboratories powered by AISight, providing early AI algorithm access, real-world data monetization, biopharma-sponsored evidence-generation studies, and clinical development partnerships to member labs.
  • Central Pathology Laboratory Operations In-house CAP/CLIA-certified GCLP histopathology lab providing end-to-end clinical trial services for biopharma partners, including receipt/processing/staining, scanning, manual central pathology reads, AI-powered reads, and reporting. Currently 12 active or upcoming trials across 8+ biopharma partners.
  • Companion Diagnostics Development & Commercialization Bespoke diagnostic assay development, AI-powered companion diagnostics, SaMD design, validation, regulatory and market access strategy, and commercialization via healthcare ecosystem partnerships for biopharma.
  • PathExplore AI-powered panel of histopathology features that spatially characterize the tumor microenvironment (TME) from H&E whole slide images with single-cell resolution, delivering >600 unique Human Interpretable Features (HIFs) per sample across 14 cancer indications. For Research Use Only.
  • LiverExplore (AIM-MASH+) AI-powered panel of >1,000 quantitative HIFs that spatially characterize liver tissue biopsy microarchitecture from H&E whole slide images for MASH and other liver diseases, including automated detection of >20 tissue regions, >10 cell types, and fibrosis subtyping. For Research Use Only.
  • IBDExplore AI-powered panel of histopathology features that spatially characterize the inflammatory microenvironment from H&E whole slide images, with 12 tissue regions, 10 cell types, and >1000 HIFs. Built and assessed on Ulcerative Colitis biopsies. For Research Use Only.
  • IHCExplore AI-powered IHC assay quantification at tissue, cellular, and subcellular resolution; extracts key histopathological features from IHC slide images and transforms IHC whole-slide images into quantitative insights for biomarker development. For Research Use Only.
  • AIM-MASH AI Assist AI-based measurement tool providing MASLD Activity Score (MAS) component grades and fibrosis stages to aid a single central pathologist for enrollment/inclusion of patients into clinical phase 2 and 3 MASH trials and evaluation of study outcomes. First AI-powered pathology Drug Development Tool with FDA and EMA qualification.
  • AIM-IHC Breast Panel AI-based measurement panel of key breast cancer biomarkers — HER2, ER, PR, and Ki-67 — fully integrated into the AISight Image Management System. Multi-clone and multi-scanner compatible with explainable AI heatmaps using additive multiple instance learning. For Research Use Only.
  • PathAssist Derm AI-powered dermatopathology workflow solution with FDA Breakthrough Device Designation that analyzes digital pathology whole slide images of skin lesions and assists pathologists in their review. For Research Use Only.
  • PLUTO / PLUTO-4 Pathology Foundation Model State-of-the-art pathology foundation model (with PLUTO-4 as latest frontier version) that enhances AI-powered pathology tools via transfer learning and fine-tuning for downstream tasks, combining histopathology images with language for multimodal disease classification.
  • AIM-HI Ulcerative Colitis (AIM-HI UC) AI-powered Geboes subgrade scoring tool assisting pathologists in accurately and reproducibly measuring histological stage for ulcerative colitis clinical trial endpoint assessment, trained on >9,000 biopsies from six clinical trials; bridges Geboes, Robarts Histopathology Index, and Nancy Histological Index scoring systems. For Research Use Only.

Companies that use PathAI

Customer profile

Ideal customer profiles3 records

PathAI technology and API

Technology

Technology focussed Yes

API detail

Has API
Yes
API docs
API detail

Core technology

AI maturity

App detail

Integration17 records

AI capability13 records

Feature11 records

PathAI partnerships and signals

Strategic signal

Recent moves8 records

Expansion highlights6 records

PathAI competitors and assessment

Company assessment

Others

  • Labcorp: Labcorp is a strategic investor in PathAI since 2019 and recently expanded collaboration to deploy AISight Dx nationwide (Feb 2026). Labcorp is both a major customer of PathAI's digital pathology platform and an anatomic pathology services competitor through its diagnostics business.

Direct peers

  • Proscia: Proscia offers a cloud-native digital pathology platform (Concentriq) with embedded AI applications and a biopharma services offering, directly competing with PathAI's AISight IMS and PathExplore products. Proscia serves similar anatomic pathology labs and biopharma customers in translational research and clinical trials.
  • Owkin: Owkin is an AI pathology and biopharma services company that builds proprietary AI models on histopathology data for drug development and diagnostic applications. Owkin's biopharma-focused AI pathology approach directly overlaps PathAI's clinical trial services and companion diagnostics offerings.
  • Ibex Medical Analytics: Ibex is a direct competitor in AI-powered cancer diagnostics, with deployments at multiple tier-1 health systems globally for prostate, breast, and gastric cancer detection. Ibex's Galen platform competes head-to-head with PathAI's AISight Dx and AIM-* diagnostic algorithms in primary diagnosis workflows.
  • Visiopharm: Visiopharm is a peer AI pathology company offering APPs for breast cancer biomarkers (ER, PR, Ki-67, HER2) and PD-L1, with IVDR clearance in EU/UK. Visiopharm is integrated as a partner algorithm within PathAI's AISight ecosystem but also competes as a standalone pathology AI platform.
  • Paige AI: Paige AI is a direct competitor in AI-powered digital pathology, offering FDA-authorized AI products for prostate, breast, and pan-cancer diagnostic pathology integrated into enterprise pathology workflows. Paige.AI's diagnostic suite directly overlaps PathAI's AIM-IHC Breast Panel and AISight Dx offerings, serving the same biopharma and anatomic pathology lab customers.

Broad incumbents

  • Tempus AI: Tempus AI is a broader precision medicine and AI-driven diagnostics company with multimodal data capabilities including pathology, genomics, and clinical data. Tempus competes in biopharma services and RWD monetization, with adjacent pathology AI capabilities that overlap PathAI's clinical trial services and data products.
  • Roche Diagnostics: Roche Diagnostics is the parent/acquirer of PathAI and a broad incumbent in the diagnostics industry with the VENTANA scanner installed base and navify digital pathology platform. PathAI's AISight IMS will integrate into Roche Diagnostics' broader portfolio upon closing of the acquisition announced May 2026.

Emerging players

  • Deep Bio: Deep Bio is a Korean AI pathology company offering CE-IVD-marked DeepDx Prostate diagnostic aid, integrated as a partner algorithm in PathAI's AISight Multi-Partner AI Portfolio. Deep Bio recently trimmed headcount and is relying on distribution partnerships including PathAI and Roche Diagnostics.
  • Mindpeak: Mindpeak is an emerging AI pathology company with CE-IVD-marked AI for breast cancer biomarker analysis (HER2, ER/PR, Ki-67) and lung PD-L1. Mindpeak is integrated into PathAI's AISight Multi-Partner AI Portfolio but also operates as an independent pathology AI vendor.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks7 records

Key highlights7 records

Customer concentration

PathAI social profiles

Digital presence

PathAI compliance and trust

Trust signal

Compliance9 records

PathAI financial estimates

Financial estimate

Revenue estimate

Valuation estimate

PathAI leadership team

Management profile

Number of profiles

Profiles15 records

PathAI subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

PathAI funding detail

Funding detail

Funding overview

Funding rounds6 records

Investors20 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

PathAI M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about PathAI

What does PathAI do?

PathAI develops and sells AI-powered digital pathology software and services. The company's flagship AISight platform (and its FDA-cleared/CE-IVD-marked AISight Dx variant) serves as a cloud-native enterprise image management system used by 100+ anatomic pathology institutions for primary diagnosis, workflow optimization, and AI-driven biomarker quantification. PathAI also operates a CAP/CLIA-certified GCLP central pathology lab delivering end-to-end clinical trial services, companion diagnostic development, and real-world histopathology data products to 8+ biopharma partners.

Is PathAI a public or private company?

PathAI is a private company. It is classified as venture growth investor backed and is currently acquired.

When was PathAI founded?

PathAI was founded in 2016. It employs 251 to 500 people.

Where is PathAI based?

PathAI is headquartered in Boston, United States, in the North America region.

How does PathAI make money?

Six revenue lines are on record. Central Pathology Lab Services are the primary driver. The others are AISight Platform SaaS Subscription, AISight Dx Enterprise IMS Licensing, real-World Data Products, companion Diagnostics Development & Commercialization and clinical Trial Services & Translational Research.

Who are PathAI's main competitors?

Labcorp is listed as an others. Direct peers are Proscia, Owkin, Ibex Medical Analytics, Visiopharm and Paige AI. Broad incumbents are Tempus AI and Roche Diagnostics. Emerging players are Deep Bio and Mindpeak.

Does PathAI have an API?

Yes. AISight Link is PathAI's open API that powers integration of third-party AI algorithms and laboratory information systems (LIS) into the AISight Image Management System, allowing partners to embed AI Impressions, Fields of Interest, and reporting tools within the AISight workflow. The API enables algorithm deployment across multiple pathologist specialties and supports integration with multi-partner AI portfolio. Specifics such as REST/GraphQL type, auth method, rate limits, versioning, or sandbox availability are not specified in available materials.

What industry is PathAI in?

PathAI's product category is AI-Powered Digital Pathology. Its primary akta.pro industry code is HLACALAC, Vendor Neutral Archive (VNA) & Enterprise Imaging Repositories, with a secondary code of HLAGAJAM, Clinical Trial Informatics (EDC/CTMS/eCOA/eTMF). Its NAICS code is 621512 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireIn Vitro Diagnostics Market to Reach US$ 170.10 Bn by 2031, Growing at 7.7% CAGR: New Report by Wissen ResearchThe global in vitro diagnostics market is projected to grow from USD 117.39 billion in 2026 to USD 170.10 billion by 2031, a CAGR of 7.7%. Growth is driven by rising disease burden, point-of-care testing, and molecular diagnostics, with molecular diagnostics expected to see the fastest CAGR at 14.7%.ChinaventureWhy is a Chinese company in the same field only worth 1 billion when American companies sell for 7 billion?Roche Diagnostics acquired PathAI for $1.05 billion in May 2026, the largest pathology AI merger to date. The deal highlights a valuation gap, as leading domestic pathology AI companies trade at 1-3 billion RMB, several times lower than PathAI.Tracxn2026 Funding Rounds & List of InvestorsPathAI has raised five funding rounds from 2017 to 2021, with amounts ranging from $4.93M to $9.55M. The rounds include Series A through Series C, with lead investors such as General Catalyst and Pillar VC. No post-money valuation or revenue multiple is disclosed.PR NewswireCancer Diagnostics Market worth $44.92 billion by 2031 - Exclusive Report by MarketsandMarkets™The cancer diagnostics market is projected to grow from $29.86 billion in 2026 to $44.92 billion by 2031, a 7.0% CAGR. Asia Pacific is expected to lead growth, and IVD testing instruments and clinical laboratories are the leading product and end-user segments.openPR.comArtificial Intelligence (AI) Pathology Quality Control Market Report Examines Leading Companies And Growth OpportunitiesThe Business Research Company released a market report projecting the AI pathology quality control market will grow from $1.78 billion in 2025 to $4.65 billion by 2030 at a CAGR of 21.1%. The report highlights key industry players and specific corporate developments, such as Molbio Diagnostics' acquisition of OptraSCAN Inc., alongside product innovations like PathAI's Artifact Detect 1 tool.GlobeNewswire[Ad-hoc-Mitteilung gemäss Art. 53 KR] Roche setzt starke Dynamik in erstem Halbjahr 2026 mit Umsatzwachstum von +6% zu konstanten Wechselkursen fort; -2% in CHF aufgrund deutlicher Aufwertung des SchwRoche reported group sales of CHF 30.4 billion in H1 2026, representing +6% growth at constant exchange rates (CER) but -2% in CHF due to Swiss franc appreciation against major currencies. The Pharma division grew +6% (CER) to CHF 23.6 billion driven by key drugs Xolair, Hemlibra, Ocrevus, Phesgo, and Vabysmo, while Diagnostics increased +3% (CER) to CHF 6.7 billion; core operating profit rose +10% (CER). The company announced multiple FDA accelerated reviews for pipeline candidates including Giredestrant, Enspryng, Tecentriq, and Gazyva, positive Phase III data for Divarasib in lung cancer, a global collaboration with Nurix Therapeutics for Bexobrutideg, and a definitive agreement to acquire PathAI for AI-powered diagnostics, while confirming its 2026 outlook for mid-single digit sales growth and high-single digit core EPS growth (CER).GenomeWebTrio of Billion-Dollar Deals Powers Dx, Tools M&A in First Half of 2026The life science tools and diagnostics industries saw significant M&A activity in H1 2026, led by Merck KGaA's $11.3 billion acquisition of Bio-Techne, alongside Astorg's $1.08 billion purchase of Thermo Fisher Scientific's microbiology business and Roche's $1.05 billion acquisition of PathAI. Nineteen full company mergers and seven asset acquisitions were announced in the first half, roughly in line with H1 2025, though below the peaks set in late 2025 when Abbott announced a $23 billion deal. Industry experts noted that the maturation of advanced diagnostics companies like Natera, Tempus AI, Guardant Health, and Caris is creating a new pool of potential acquirers, while Alamar Biosciences' $220 million IPO was seen as an encouraging sign for the tools space.GurufocusRoche Acquires PathAI for $750 Million, Stock Impact ExpectedRoche agreed to acquire PathAI for $750 million upfront, with up to $300 million more on milestones, expected to close in H2 2026. The deal integrates PathAI's AISightIMS AI pathology software into Roche's diagnostics division. The body also contains unrelated SMCI stock analysis.36krWhy Was This AI Pathology Startup Sold for 5 Billion Yuan in an AllRoche Diagnostics announced the signing of a definitive merger agreement to acquire PathAI, an AI pathology company, for $750 million upfront (approximately RMB 5.099 billion) with additional milestone payments up to $300 million, totaling up to $1.05 billion, with completion expected in H2 2026. PathAI has developed the world's first AI-driven pathological drug development tool (AIM-MASH AI Assist) certified by both the FDA and EMA, and operates the Precision Pathology Network, a digital anatomical pathology laboratory network, with 90% of the top 15 global biopharmaceutical companies as customers. The acquisition aims to integrate PathAI's complete digital pathology technology stack with Roche Diagnostics' global companion diagnostic business and oncology drug pipeline to create an end-to-end solution from tissue staining to companion diagnosis.